Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 77

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 77
---
 COVID-19 and individuals continue to respond
to the fear of contracting COVID-19. It is not possible to accurately predict the extent of the adverse effects of the pandemic on
our business. However, we have experienced certain impacts and may experience others which, if they continue for an extended period of
time, could have material adverse effects on our operations and the execution of our business plans. For example, we experienced some
delays in our clinical trials, in particular our Phase 1 trials of MTX110 in DMG at Columbia University and in medulloblastoma at the
University of Texas. Individuals defer seeking treatment, physicians have fewer in-person meetings to recruit and enroll patients, and
recruited patients are hindered by restrictions in traveling to and accessing clinical sites. In addition, resources at hospitals have
been diverted to dealing with the pandemic, causing delays in scheduling screening evaluations, implant procedures, and follow-up monitoring
visits. As a result of the foregoing factors, the expected timeline for data readouts of our clinical trials may be negatively impacted,
which would adversely affect our business.

| 38 |

The extent to which fear of exposure to or actual effects of COVID-19, new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the United States, United Kingdom and international healthcare systems, the United States, United Kingdom and worldwide economy; the timing, scope and effectiveness of United States, United Kingdom and international governmental response; and the impact on the health, well-being and productivity of our employees. To the extent that pandemics or disease outbreak, such the COVID-19 pandemic, adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “ Risk Factors” section.

Risks related to our intellectual property

Our success depends in part on our ability to protect rights in our intellectual property, which cannot be assured.

Our success and ability to
compete effectively are in large part dependent upon exploitation of proprietary technologies and products that we have developed internally
or have acquired or in-licensed. To date, we have relied on copyright, trademark and trade secret laws, as well as confidentiality procedures,
non-compete and/or work for hire invention assignment agreements and licensing arrangements with our employees